a public good project by the
Synthesis
Company
of California

© 2026

Federico Bolognani | doi.page

0 works0 citations0 h-index

Federico Bolognani

Ironwood Pharmaceuticals (United States)(US)Ensemble Therapeutics (United States)(US)

Publications by Year

Research Areas

Clinical Nutrition and Gastroenterology, Autism Spectrum Disorder Research, Diet and metabolism studies, RNA Research and Splicing, Electrolyte and hormonal disorders

Most-Cited Works

→ LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice(2011)365 cited
→ Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials(1999)314 cited
→ RNA–protein interactions and control of mRNA stability in neurons(2007)212 cited
→ Role of HuD and other RNA‐binding proteins in neural development and plasticity(2002)202 cited
→ Patients with autism spectrum disorders display reproducible functional connectivity alterations(2019)177 cited
→ Adaptive behavior in autism: Minimal clinically important differences on the Vineland‐II(2017)169 cited

→ A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder(2019)

124 cited

→ Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States(2017)120 cited

→ Novel recognition motifs and biological functions of the RNA-binding protein HuD revealed by genome-wide identification of its targets(2009)114 cited

→ Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial(2022)102 cited